Edition:
United States

Bio Rad Laboratories Inc (BIO.N)

BIO.N on New York Stock Exchange

261.48USD
4:02pm EDT
Change (% chg)

$0.80 (+0.31%)
Prev Close
$260.68
Open
$260.65
Day's High
$263.53
Day's Low
$260.65
Volume
11,777
Avg. Vol
33,530
52-wk High
$278.99
52-wk Low
$209.13

Chart for

About

Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a... (more)

Overall

Beta: 0.95
Market Cap(Mil.): $9,097.26
Shares Outstanding(Mil.): 34.88
Dividend: --
Yield (%): --

Financials

  BIO.N Industry Sector
P/E (TTM): 149.82 35.59 33.60
EPS (TTM): 1.74 -- --
ROI: 1.46 14.13 13.19
ROE: 1.89 16.91 15.00

BRIEF-Bio Rad Laboratories Says KPMG Notified Senior Management It Required More Time To Complete Audit Of 2017 Financial Statements

* BIO RAD LABORATORIES - KPMG NOTIFIED SENIOR MANAGEMENT IT REQUIRED MORE TIME TO COMPLETE AUDIT OF 2017 FINANCIAL STATEMENTS - SEC FILING

Mar 16 2018

BRIEF-Bio Rad Laboratories Files For Non-Timely 10-K - SEC Filing

* BIO RAD LABORATORIES FILES FOR NON-TIMELY 10-K - SEC FILING Source text (http://bit.ly/2FeZn29) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 02 2018

BRIEF-Bio-Rad Q4 Earnings Per Share $2.32

* BIO-RAD REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Feb 27 2018

BRIEF-Bio-Rad Gains Additional U.S. FDA Clearances

* BIO-RAD GAINS ADDITIONAL U.S. FDA CLEARANCES FOR BLOOD TYPING PRODUCTS, EXPANDING ITS OFFERING FOR BLOOD TESTING MARKET Source text for Eikon: Further company coverage:

Jan 22 2018

BRIEF-Bio-Rad Authorizes New $250 Million Share Repurchase Program

* BIO-RAD AUTHORIZES NEW $250 MILLION SHARE REPURCHASE PROGRAM

Nov 28 2017

BRIEF-Bio Rad Laboratories reports Q3 earnings per share $0.91

* Bio Rad Laboratories Inc reports third-quarter 2017 financial results

Nov 02 2017

Earnings vs. Estimates